Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04724668 · ClinicalTrials.gov registry record · NA
The Role of the Circadian System in Binge Eating Disorder
A NA study of Binge-Eating Disorder and Circadian Rhythm Disorders, sponsored by University of Cincinnati.
- Completed
- Registry status
- NA
- Development phase
- 43
- Enrollment target
- 1
- Study location
NCT04724668: Completed NA study of Binge-Eating Disorder and Circadian Rhythm Disorders, sponsored by University of Cincinnati.
NCT04724668 is a NA study of Binge-Eating Disorder and Circadian Rhythm Disorders that has completed, run by University of Cincinnati. The registered enrollment target is 43 participants, below the 1,142-participant average among 37 other Binge-Eating Disorder trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04724668, a NA study of Binge-Eating Disorder and Circadian Rhythm Disorders, has completed, sponsored by University of Cincinnati.
- COMPLETED
- Registry status
- NA
- Development phase
- 43 participants
- Enrollment target
- 1
- Study location
Study Summary
Binge eating disorder (BED) shows prominent circadian features that suggest a delay in circadian phase, and preliminary evidence shows binge eating may be responsive to chronobiological interventions, implicating a circadian system dysfunction in its pathophysiology. What remains lacking, however, is comprehensive knowledge of the characteristics of circadian system dysfunction in BED, and whether this dysfunction represents a therapeutic target in BED. There is therefore a critical need to characterize circadian system dysfunction in BED, and evaluate it as a potential therapeutic target. Without such information, the understanding on the role of the circadian system in BED and its potential as a new therapeutic target will remain limited.
Primary Outcome
Difference in mean DLMO (measured in hours) between subjects with binge eating disorder (BED) and control subjects without BED.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Melatonin (3hrs before DLMO)
- DIETARY_SUPPLEMENT Placebo (3hrs before DLMO)
- DEVICE Morning light version 1
- DEVICE Morning light version 2
Study Locations (1)
Ohio
- Lindner Center of HOPE / University of Cincinnati - Mason
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2021-01-15 |
| Est. Completion | 2025-05-30 |
| Phase | NA |
What the finished NCT04724668 record still lists
NCT04724668 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 1,142-participant average among 37 other Binge-Eating Disorder trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Binge-Eating Disorder appearing as the primary indexed condition, and to 4 interventions - of which Melatonin (3hrs before DLMO) is the first listed.
NCT04724668 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT04724668 about?
NCT04724668 is a clinical study titled "The Role of the Circadian System in Binge Eating Disorder". Binge eating disorder (BED) shows prominent circadian features that suggest a delay in circadian phase, and preliminary evidence shows binge eating may be responsive to chronobiological interventions, implicating a circadian system dysfunction in its pathophysiology. What remains lacking, however, i...
What is the current status of trial NCT04724668?
This trial is currently completed. It is a NA study. The enrollment target is 43 participants. The study started on 2021-01-15. Estimated completion is 2025-05-30.
What conditions does trial NCT04724668 study?
This clinical trial studies the following conditions: Binge-Eating Disorder, Circadian Rhythm Disorders.
What interventions are being tested in trial NCT04724668?
The interventions under investigation include: Melatonin (3hrs before DLMO) (DIETARY_SUPPLEMENT), Placebo (3hrs before DLMO) (DIETARY_SUPPLEMENT), Morning light version 1 (DEVICE), Morning light version 2 (DEVICE).
Who is sponsoring clinical trial NCT04724668?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04724668 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Binge-Eating Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04724668's enrollment target sits among peer trials
43 26th of 37 higher than 12 of 37 other Binge-Eating Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Binge-Eating Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Use of Circadian Reset Technology to Alter REM Sleep and Appetitive Control in Patients With Binge Eating Disorder
RECRUITING · NA
-
Developing an Artificial Intelligence (AI) Chatbot for Adolescents and Young Adults With Eating Disorders
RECRUITING · NA
-
Treating Binge Eating and Obesity Digitally in Black Women
RECRUITING · NA
-
Preventing Type 2 Diabetes in Black Emergent Adult
RECRUITING · NA
-
Study Comparing Acceptance and Commitment Therapy to Supportive Diabetes Counseling and a Waitlist Control for Eating Disorders in Type 1 Diabetes
RECRUITING · NA
-
Building an Equitable and Accessible System of Eating Disorder Care for VA, DoD, and Underrepresented Americans
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI